LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MAIA
MAIA Biotechnology, Inc.
There isn't enough reported data to score MAIA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MAIA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MAIA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MAIA PE Valuation
MAIA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MAIA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect MAIA's earnings, revenue and profitability to hold roughly steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MAIA on earnings quality, reporting a profit while its opponent remains loss making.
MAIA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$0.21 |
| Q2 2026 | -$0.63 | -$0.10 |
| Q1 2026 | -$0.68 | +$0.07 |
| Q4 2025 | -$0.70 | +$0.35 |
| Q3 2025 | -$0.69 | +$0.68 |
| Q2 2025 | -$0.53 | +$1.09 |
| Q1 2025 | -$0.75 | +$0.82 |
| Q4 2024 | -$1.05 | +$0.44 |
MAIA is still losing money, but far less than before: $0.48 per share over the past year, against $1.67 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
MAIA Quarterly Revenue
MAIA's revenue is shrinking: $0 last quarter.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MAIA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MAIA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.3M | -$2.8M |
| Q2 2026 | -$6.8M | -$2.6M |
| Q1 2026 | -$5.3M | -$1.1M |
| Q4 2025 | -$7M | -$3.1M |
| Q3 2025 | -$3.5M | +$38.2K |
| Q2 2025 | -$4.1M | +$549.4K |
| Q1 2025 | -$4.2M | -$615.5K |
| Q4 2024 | -$3.9M | +$84.3K |
MAIA has burned cash in almost every quarter: −$25M over the past year, against −$16M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MAIA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MAIA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +70.6K shares |
| 1 year | +101% | +30.6M shares |
| 3 years | +556% | +51.6M shares |
| 5 years | +472% | +50.2M shares |
MAIA has 61M diluted shares, up 101% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MAIA Net Leverage
MAIA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MAIA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 6.9 | Oversold |
MAIA's weekly RSI is 34 (neutral) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MAIA PE vs Healthcare Sector
MAIA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MAIA on trend strength, trading above more of its moving averages.
MAIA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.13 | 11% below |
| 20 week MA | $1.26 | 20% below |
| 50 week MA | $1.44 | 30% below |
| 100 week MA | $1.56 | 35% below |
| 200 week MA | $2.06 | 51% below |
MAIA is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MAIA on returns for 2026, with the stronger performance.
MAIA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $5.80 | $3.35 | -42% |
| 2023 | $3.35 | $1.17 | -65% |
| 2024 | $1.17 | $2.09 | +79% |
| 2025 | $2.09 | $1.57 | -25% |
| 2026 YTD | $1.57 | $1.01 | -36% |
MAIA has finished lower in three of the last four years. It's down 36% so far in 2026.